Spain's drug industry body Farmaindustria says it has been worried about the violation of the right to prescription freedom that can result from the order that the Government of Aragon put out at end-October that establishes the creation of a unique pharmacotherapeutic guide and of forced fulfilment for all hospitals.
Jose Ramon Luis-Yague, a director of Farmaindustria, has explained that 'the law grants competitions to the autonomies in the rational use of medicines, but these measures in no way can change the rules of the market nor limit patients' access to drugs. The mechanism to decide what drugs finance corresponds to the Ministry of Health." In its opinion, the order dictated by Aragon establishes that there will be a unique catalog of prescriptions for all hospitals and that breaks the rules of the game. It is contrary to prescribing freedom, said Farmaindustria.
The management of Farmaindustria recently had a meeting with the press in Cordova, when concern was expressed about the declarations of the Madrilenian advisor of Health, Juan Jose Guemes, who only days ago raised the subject of modifying the system of reference prices, at the moment based on maximum prices for active principles, to one based on therapeutic groups:
"It is an erroneous proposal from the health, technical and economic point of view. He would prevent the development of new drugs and he would not stop costs," explained the chief of Farmaindustria's directorate, Humberto Harness, who anticipates meeting with Mr Guemes in the next days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze